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Background—In retrospective studies, loss of p27Kip1 (p27), a cyclin dependent kinase
inhibitor, has been associated with poor prognosis following colorectal cancer treatment. In a
prospective study, we validated this relationship in patients enrolled on a trial of adjuvant
chemotherapy for Stage III colon cancer.
Methods—Cancer and Leukemia Group B (CALGB) protocol 89803 randomized 1264 stage III
colon cancer patients to receive weekly bolus fluorouracil/leucovorin (5FU/LV) or weekly bolus
irinotecan, fluorouracil, and leucovorin (IFL). The primary endpoint was overall survival (OS);
disease-free survival (DFS) was a secondary endpoint. Expression of p27 and DNA mismatch
repair (MMR) proteins were determined by immunohistochemistry (IHC) in primary tumor and
normal tissue from paraffin blocks. Data were analyzed using logrank test.
Results—Of 601 tumors analyzed, 207 (34.4%) demonstrated p27 loss, 377 (62.8%) retained
p27, and 17 (2.8%) were indeterminate. Patients with p27 negative tumors showed reduced OS (5-
year 66%; 95%CI 0.59-0.72 vs. 75%; 95%CI 0.70-0.79, logrank p=0.021). This relationship was
not influenced by treatment arm. Combination of p27 status with MMR status, however, identified
a small subset of patients that may benefit from IFL (n=36; 5-year DFS 81%; 95%CI 0.64-0.98 vs.
47%; 95%CI 0.21-0.72, logrank p=0.042; 5-year OS 81%; 95%CI 0.64-0.98 vs. 60%; 95%CI
0.35-0.85; logrank p=0.128).
Conclusions—Loss of p27 is associated with reduced survival in stage III colon cancer, but by
itself does not indicate a significant difference in outcome between patients treated IFL or 5FU-
LV.
Keywords
Colorectal cancer; adjuvant therapy; biomarkers
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States,
accounting for approximately 49,000 deaths per year (1). CRC treatment depends upon
disease stage. Patients with localized disease receive surgery with or without radiation
therapy, whereas local treatment combined with systemic chemotherapy is indicated for
patients demonstrating locally advanced tumors or tumors with locoregional metastases. In
general, patients with distant metastatic disease are managed by chemotherapy alone,
although an increasing body of data suggests that a subset of these patients with isolated
hepatic or pulmonary metastases achieve a significant 5-year survival when the metastases
are resected (2). Unfortunately, even though treatment decisions depend upon disease stage,
conventional histopathological staging methods cannot accurately predict disease behavior.
For example, approximately 40% of patients with stage III disease will develop recurrence
following surgery and adjuvant chemotherapy. Adjuvant chemotherapy and aggressive
surgery carry morbidities and should ideally only be employed for patients who can benefit
from these treatments. The variation in clinical behavior found in the current CRC staging
system implies that a significant proportion of patients with CRC are currently either over-
or under-treated.
Originally identified in cells whose growth was arrested by TGF-α, p27 is a regulatory
element of the cell cycle that suppresses the G1-S transition by inhibiting cyclin-dependent
kinase activity (3-6). Reduced or absent p27 expression is found in many human
malignancies, particularly those of epithelial origin (7-10). Human cancer studies showed
that loss of p27 protein is rarely due to inactivation or mutation of the p27 gene (6,11,12).
Instead, most tumors lacking p27 expression demonstrate elevated expression of ubiquitin
ligase and cofactor proteins that target p27 for proteosomal degradation (13,14).
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Retrospective studies showed that p27 expression is associated with a poor prognosis in a
variety of epithelial tumors, including those of colon, gastric, breast, prostate, and lung
origin (7-9). In a study of 149 surgically resected colon cancers, Loda et al found a
significantly improved median overall survival (OS) for patients whose tumors expressed
p27 in more than 50% of the cells (241 months), compared to those with expression in less
than 50% of cells (149 months) or for which p27 expression was absent (69 months) (7).
Multivariate analysis showed that both disease stage and p27 expression were independent
indicators of overall survival for this cohort. Other small retrospective studies confirmed this
result and also found that low p27 levels are more frequent in right-sided colon cancers
(15-19) and predict future development of metastatic disease (20,21).
CALGB Protocol 89803 was a prospective randomized trial comparing adjuvant
chemotherapy using 5-FU and leukovorin (FU/LV) to 5-FU, LV and irinotecan (IFL),
administered for 32 and 30 weeks, respectively, following the resection of a stage III colon
cancer. This trial showed no difference in either DFS or OS between the 5-FU/LV and IFL
treatment arms. This trial also prospectively assessed the effect of tumor p27 status by
immunohistochemistry upon DFS and OS, and determined the relationship between tumor
p27 status and other markers of tumor behavior.
Materials and Methods
Characteristics of Study Population
All patients enrolled on CALGB protocol 89803, had histologically confirmed stage III
colon cancer. All patients underwent definitive surgical resection, and started treatment no
earlier than 21 days and no later than 56 days following resection. The primary objective
was to compare OS between the two treatment arms; DFS was compared as a secondary
objective. Additional secondary aims addressed the relationship between tumor-associated
risk factors and treatment outcome, and required submission of paraffin blocks containing
tumor and normal tissue to the CALGB Pathology Coordinating Office (PCO) at Ohio State
University. This protocol was reviewed by the institutional review board of each
participating center and all patients gave written informed consent prior to participation.
Trial Structure and Organization
This trial was written and coordinated by CALGB with participation by the North Central
Cancer Treatment Group (NCCTG), National Cancer Institute of Canada Clinical Trials
Group (NCIC-CTG), Eastern Cooperative Oncology Group (ECOG), Southwest Oncology
Group (SWOG), and the NCI Cancer Trials Support Unit (CTSU). The CALGB data safety
monitoring board reviewed safety data semi-annually and efficacy data at protocol specified
intervals in accordance with CALGB policies and procedures.
Treatment
Eligible patients were assigned electronically (randomized fixed block) using central
registration to receive either IFL or 5FU/LV. The 5FU/LV group received leucovorin 500
mg/m2 intravenously over two hours, with a bolus of 5FU 500 mg/m2 given by intravenous
injection at one hour after initiation of leucovorin. Treatments were scheduled to be
administered weekly for six consecutive weeks followed by a two week rest, for a total of
four cycles or 32 weeks of total therapy. The IFL group received irinotecan 125 mg/m2 over
90 minutes followed immediately by an intravenous bolus injection of leucovorin 20 mg/m2
and then 5FU 500 mg m2 also by intravenous bolus injection. Treatment was scheduled to
be given for four consecutive weeks followed by a two week rest for five cycles or a total of
30 weeks. Further details concerning the treatment portion of this trial have been published
previously (22).
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Characterization of tumor p27 status
Formalin-fixed, paraffin-embedded specimens from 601 patients out of a total of 1264
enrolled on CALGB protocol 89803 were studied. Central pathology review confirmed the
histology of each specimen, and blocks were sectioned at 4μm. Laboratory analysis of tissue
specimens was performed without knowledge of the patient’s clinical outcome or treatment
regimen.
Immunohistochemistry (IHC) was used to detect the presence of p27, MLH1 and MSH2
proteins in primary tumor specimens, using methods described in previous reports
(15,19,23). Positive controls were provided by examining staining of normal colonic mucosa
from each case; tumors known to lack p27, MLH1 or MSH2 were stained concurrently and
served as negative controls. A number of different scoring systems have been used for p27
studies (7,16,19,24). In this report, we scored the tumors using a modification of our
previous methods that we believe provides best reproducibility, and yields the same outcome
result as that using our previous scoring method (data not shown) (7). Nuclear expression of
p27 was evaluated in a total of 10 randomly-selected high powered fields per tumor. A
tumor cell was counted as p27 positive when its nuclear reaction was equal to or stronger
than the reaction in surrounding lymphocytes, which were used as an internal control. All
cases were scored as either positive (≥ 10% of tumor cells with strong nuclear staining),
negative (<10% of tumor cells with strong nuclear staining), or non-informative (Figure 1).
Cases designated as mismatch repair deficient (MMR-D) were those with a negative IHC
score for either MLH1 or MSH2, and cases designated mismatch repair intact (MMR-I)
retained expression of both proteins. A single study pathologist (E.M.) scored all p27
immunostains. For MLH1 and MSH2, each case was scored by two independent reviewers
(CCC, HPH). In cases of disagreement, a third reviewer (MR) examined the case to provide
the final score.
Statistical methods
The goal of this correlative study was to determine whether tumor p27 status predicted
treatment outcome for patients with stage III colon cancer. The primary endpoint of this
study was OS measured from entry onto the clinical trial until death from any cause. DFS
was also considered as a study endpoint. A secondary goal was to determine the relationship
between tumor p27 status and MMR status, as determined by IHC. The logrank test was
used to make survival comparisons among categories defined by MMR status and within
treatment and MMR subgroups. The proportional hazards model was used to make survival
comparisons controlling for treatment and other clinico-pathologic factors. The Kaplan-
Meier method was used to estimate the DFS and OS curves and 5-year survival
probabilities. Data were analyzed with continued follow-up for DFS and OS as of March 10,
2008. All statistical analyses were performed by CALGB statisticians.
Results
Clinical and pathological differences between p27 intact and p27 deficient tumors
We examined the relationship between p27 status and other variables associated with tumor
behavior (Table 1). Tumors were available for analysis for 601 of a total of 1283 patients
randomized to CALGB 89803 . There was no difference between treatment outcome in
either experimental arm when patients with available tumors were compared to the entire
study cohort (data not shown). Of 601 tumors analyzed, 207 (34.4%) demonstrated loss of
p27 expression, 377 (62.8%) retained p27 expression, and 17 (2.8%) were indeterminate.
Compared to those with intact p27 by IHC, p27 negative tumors were more likely to be
proximal (68.6% vs. 50.9%, p<0.0001). Tumors lacking p27 were also more likely to be
poorly differentiated (grade III/IV in 33.3% vs. 18.5%, p<0.0001). The nodal ratio, i.e. the
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number of positive nodes divided by the total number of nodes examined, was higher for
p27 deficient cases (0.33 vs. 0.28, p=0.017) (Table 1). There were no differences between
p27 deficient and p27 intact tumors in the proportion of male patients, patient age, or the
number of positive nodes per case.
Loss of p27 is associated with reduced OS and DFS in stage III colon cancer
Comparisons of 5-year DFS and OS for p27 deficient and p27 intact cases are shown in
Table 2 and Figure 2. The median duration of follow-up was 6.58 years. Patients enrolled on
CALGB 89803 whose tumors were deficient in p27 had a 5-year OS that was 12.0% less in
relative terms than those with intact p27 (logrank p=0.021). This same trend was observed
for DFS, although the difference was not significant when assessed by the logrank test
(9.7% relative decrease at 5 years, p=0.187).
Addition of irinotecan to 5-FU + LV does not improve treatment outcome for patients with
p27 deficient tumors
For the 1264 patients treated on CALGB protocol 89803, addition of irinotecan to 5-FU/LV
did not improve 5-year DFS or OS (22). We examined the impact of tumor p27 status upon
treatment outcome for either 5FU/LV or IFL. The results are presented in Table 3. This
analysis showed that p27 intact and p27 deficient tumors responded similarly to adjuvant
treatment with 5-FU/LV and IFL.
p27 status may help predict OS
In a multivariate analysis of p27 status (intact; deficient), treatment arm (IFL; 5FU/LV), age
(years, continuous), gender (male; female), tumor location (distal; proximal), tumor
differentiation (grades I/II; grades III/IV), tumor invasion (T1/T2; T3/T4), extracellular
mucin (≤ 50%; > 50%), and nodal ratio (number of positive nodes versus number of nodes
sampled), only nodal ratio (logrank p<0.0001; HR=3.91) significantly predicted DFS. When
predicting OS, nodal ratio (logrank p<0.0001; HR=4.38) and p27 status (logrank p=0.0448;
HR=0.742) remained significant at α=0.05.
Relationship between tumor p27 status and microsatellite instability
We determined tumor MMR status using IHC to identify loss of expression of either of two
mismatch repair proteins, MLH1 or MSH2. We found no difference in outcome for MMR-D
compared to MMR-I tumors (Table 2). In additional studies of this same cohort, we
compared tumor IHC and genotyping using Bethesda criteria microsatellite loci (25). This
analysis showed that these two methods of identifying mismatch repair deficiency were
equivalent for predicting treatment outcome. In this study, we chose MLH1 and MSH2 IHC
for study in combination with p27 IHC because results obtained with this common method
could be readily applied to clinical practice. Like the p27 deficient tumors examined here,
colon cancers that exhibited MMR-D were more likely to be proximally located (91.5% vs
51.3%, p<0.0001) and poorly differentiated (49.0% vs 21.0%, p<0.0001) than those that
were MMR-I. Also like p27 deficient tumors, MMR-D cases had a lower nodal ratio than
MMR-I cases (0.18 vs. 0.23, p=0.005). MMR status was determined by IHC on 589 tumors
for which p27 status was known. The results are shown in Table 3. Tumors deficient in p27
were more likely to be MMR-D than tumors with intact p27 (p=0.0017). Tumors that were
MMR-D and p27 intact had the best outcome, with a 19.6% increase in DFS at 5 years
(67%; 95% CI 0.52, 0.83 vs 56%; 95% CI 0.48, 0.64, logrank p=0.268), and a 14.1%
increase in OS at 5 years (73%; 95% CI 0.58, 0.88 vs 64%; 95% CI 0.56,0.71, logrank
p=0.219). This is in comparison to the category with the worst outcome, which included
patients with p27 deficient, MMR-I tumors (Table 3 and Figure 3).
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In a previous analysis of this cohort, we showed that patients with MMR-D tumors
experienced similar treatment outcome when compared to those whose tumors were MMR-I
(25). However, this same prospective study found that patients with MMR-D tumors may be
more likely to benefit from IFL. To explore the relationship between the predictive value of
tumor MMR determination and the prognostic value of tumor p27 status, we examined
treatment outcome for cases from CALGB 89803 for which both p27 and MMR status were
known (Table 3). This analysis identified the p27 deficient, MMR-D subset as one that may
benefit from the irinotecan-containing regimen, with 72% better 5-year DFS (logrank
p=0.042), and 35% better 5-year OS (logrank p=0.128) for the IFL arm (Figure 3).
Discussion
Our results indicate that tumor p27 status is a prognostic factor for patients receiving
adjuvant chemotherapy following surgery for stage III colon cancer, as patients with p27
deficient tumors treated with either FU/LV or IFL had a 5-year OS that was 12% less than
those with p27 intact tumors. When the interaction between p27 status and treatment was
examined, we found that loss of p27 did not predict improved response to the irinotecan-
containing regimen used in this study. As a result, tumor p27 status, taken alone, is not
currently useful in guiding choice of adjuvant chemotherapy. However, low levels of p27 in
colorectal cancers result from enhanced ubiquitin-dependent degradation of this tumor
suppressor, and recent studies identified the ubiquitin ligase, Pirh2, as a major effector of
p27 degradation. These studies confirmed an inverse relationship between p27 and Pirh2
expression in colorectal cancer (26), suggesting that selective inhibition of Pirh2 would be
beneficial in treating patients with p27 deficient tumors.
In an analysis from the Nurses Health Study and the Health Professional Follow-up Study,
Ogino, et. al. examined the relationship between tumor MSI and p27 status for 634 cases of
colorectal cancer that developed during prospective follow-up (27). Using a definition of
p27 status similar to that employed here, they found that 36.4% of cancers were p27
deficient, and 16.6% exhibited MSI-H (27). MMR status in this study was determined by
tumor genotyping to identify high levels of microsatellite instability (MSI-H), rather than
IHC. These investigators found that p27 deficient tumors were more likely to be MSI-H
(26.0% p27 deficient/MSI-H, 11.2% p27 deficient/MSS or MSI-L, p<0.001). Our results are
consistent with this, as 19.2% of the p27 deficient cases were MMR-D, compared to 9.1% of
those with intact p27.
A study of the relationship between treatment outcome and tumor MMR status for this same
cohort suggested that MMR-D status predicted improved IFL response, although MMR
status was not a significant prognostic factor overall (25). We therefore performed an
exploratory analysis combining a prognostic factor (tumor p27 status) with a predictive
factor (tumor MMR status). The p27 deficient tumors in this series showed some similarities
to those that were MMR-D, as these categories were both associated with proximal location,
poorly differentiated histology, and higher nodal ratio. Despite these similar
clinicopathologic characteristics, p27 deficient and MMR-D tumors show distinct clinical
behavior. While patients with p27 deficient tumors have a worse outcome, those with MMR-
D tumors generally have a better prognosis, or at least do not demonstrate the aggressive
behavior typical of poorly differentiated cancers (28,29). In this trial, both treatment arms
contained 5FU+LV, and we found no difference in outcome for the MMR-D and MMR-I
cases, although there was a trend toward improved 5-year DFS in those with MMR-D
tumors (0.67 vs 0.60, p=0.18). In addition, we found that only 18% of tumors that were p27
deficient were also MMR-D. Given these results, we predicted that the best outcome would
be observed for patients whose tumors were p27 intact and MMR-D, and the worst outcome
for those whose tumors were p27 deficient and MMR-I. This was what we observed for the
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DFS analysis, although the 19.6% difference in DFS between the categories with the best
outcome (p27 intact, MMR-D) and worst outcome (p27 deficient, MMR-I) was not
statistically significant (logrank p-value for this comparison = 0.219).
This trial allowed us to explore whether a combination of tumor p27 and MMR status
predicted better response to IFL. Although the sample size is small, patients whose tumors
were both p27 deficient and MMR-D had a DFS that was improved by 72% (logrank
p=0.042) and OS that was improved by 35% (logrank p=0.128) when they received the
regimen containing irinotecan. This relationship was not observed in tumors that were p27
intact/MMR-D, p27 intact/MMR-I, or p27 deficient/MMR-I. This subset analysis of a small
number of samples in the p27 deficient, MMR-D category (N=36) must be interpreted with
caution, however several factors make these data intriguing. First, this study was a pre-
specified prospective analysis of both MMR and p27 as markers of disease response and
treatment outcome, and is therefore free of the bias inherent in retrospective tumor bank
studies. Similarities in marker frequency and tumor location between p27 deficient and
MMR-D tumors suggest a biological relationship between these factors. It is possible that
this yet unidentified relationship is responsible for enhanced tumor sensitivity to irinotecan.
These results provide important insight into the ways in which prognostic and predictive
factors can interact, potentially leading to inaccuracy when single factors are used to predict
disease behavior. Tumors that are p27 deficient are less likely to respond to adjuvant
chemotherapy, an effect that is largely independent of treatment. However, tumors that are
p27 deficient are also somewhat more likely to exhibit MMR-D, a condition that appears to
convey a differential response to chemotherapy in this colon cancer adjuvant treatment trial.
This study, therefore, illustrates the importance of testing prognostic and predictive factors
in large randomized trials where the relationships between treatment and multiple tumor-
specific variables can be assessed.
Statement of Translational Relevance
The current AJCC staging system for colon cancer is insufficient, as evidenced by a wide
variation in adjuvant treatment outcome among patients with stage III disease. In this
prospective study of adjuvant chemotherapy following surgery for stage III colon cancer,
we showed that loss of tumor p27 expression is associated with post-treatment disease
recurrence. This prognostic result allows clinicians to subdivide stage III colon cancer
into high- and low-risk groups, and identifies p27 signaling pathway as a potential target
for new agent development.
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Variable p27 expression in stage III colon cancer.
A,B: Normal controls, human colon;
C: Adenocarcinoma, colon p27 positive;
D: Adenocarcinoma, colon, p27 negative
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Kaplan-Meier plots for DFS and OS comparing patients with p27 intact tumors to those with
p27 deficient tumors.
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Top: Kaplan-Meier plots for DFS and OS for patients with p27 deficient, MMR-D tumors
comparing those treated with IFL to those treated with 5FU/LV.
Bottom: Kaplan-Meier plots for DFS and OS comparing patients with p27 intact, MMR-D
tumors to those with p27 deficient, MMR-I tumors.
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Table 3A




p27 intact cases p27 deficientcases, p=
MMR-D – n (%) 74 (12.6) 34 (9.1) 36 (18.1) 0.0017
MMR-I – n (%) 515 (87.4) 341 (90.9) 163 (81.9)
 Total 589 375 199
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Table 3B
Prognostic and predictive values of combined p27; MMR variable
n= 5-year Disease-freeSurvival 5-year Overall Survival
Prognostic
p27intact/MMR-D 34 0.67 (0.52, 0.83) 0.73 (0.58, 0.88)
p27 intact/MMR-I 341 0.62 (0.57, 0.68) 0.75 (0.70, 0.80)
p27 deficient/MMR-D 36 0.66 (0.51, 0.82) 0.72 (0.57, 0.87)
p27 deficient/MMR-I 163 0.56 (0.48, 0.64) 0.64 (0.56, 0.71)
 Logrank p 0.347 0.079
Predictive
p27intact/MMR-D 34
  5-FU/LV 18 0.61 (0.38,0.83) 0.72 (0.51,0.93)
  IFL 16 0.75 (0.54, 0.96) 0.75 (0.54, 0.96)
 Logrank p 0.358 0.856
p27 intact/MMR-I 341
 5-FU/LV 174 0.66 (0.59, 0.73) 0.77 (0.70, 0.83)
 IFL 167 0.59 (0.51, 0.66) 0.73 (0.66, 0.80)
 Logrank p 0.233 0.661
p27 deficient/MMR-D 36
 5-FU/LV 15 0.47 (0.21, 0.72) 0.60 (0.35, 0.85)
 IFL 21 0.81 (0.64, 0.98) 0.81 (0.64, 0.98)
 Logrank p 0.042 0.128
p27 deficient/MMR-I 163
 5-FU/LV 76 0.56 (0.45, 0.67) 0.66 (0.56, 0.77)
 IFL 87 0.56 (0.46, 0.67) 0.61 (0.51, 0.72)
 Logrank p 0.957 0.845
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